PM · News · 20260918N
ZYN Product Portfolio Expansion
Philip Morris International Inc. · 2026-09-18 · Importance 34 · Surprise 42 · In source text
PMI recently announced expansions to its ZYN nicotine pouch portfolio. New ZYN products have received FDA authorization, supporting broader availability of the smoke-free portfolio in the United States. The developments position ZYN alongside IQOS as a principal growth product in PMI’s reduced-risk offering.
Key facts
- The company announced expansions to its Zyn nicotine pouch portfolio. source
- Recent developments include FDA authorization for new ZYN products. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | The company announced expansions to its Zyn nicotine pouch portfolio. |
| revenue | positive | probable | — | Recent developments include FDA authorization for new ZYN products. |